The stock is now down more than 25% for the year and more than 80% from its all-time high, set earlier this year. With that kind of decline, some investors may wonder if it's a stock with some value ...

At the start of 2023, U.S. patent exclusivity expired for the blockbuster drug Humira, AbbVie's chief cash cow. During the 20 years the immunosuppressive drug has been on the market, it brought in ...